Manufacturer of Controlled Substances, Notice of Application, Lin Zhi International, Inc., 30332 [2013-12110]
Download as PDF
<![CDATA[
30332
Federal Register / Vol. 78, No. 99 / Wednesday, May 22, 2013 / Notices
Drug
Schedule
2C-E (2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine) (7509) .......................................................................................................................
2C-H (2-(2,5-Dimethoxyphenyl)ethanamine) (7517) ...................................................................................................................................
2C-1(2-(4-lodo-2,5-dimethoxyphenyl)ethanamine) (7518) ..........................................................................................................................
2C-C (2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (7519) ......................................................................................................................
2C-T-4 (2-(4-isopropylthio)-2,5-dimethoxyphenyl) ethanamine) (7532) ......................................................................................................
Dihydromorphine (9145) ..............................................................................................................................................................................
Heroin (9200) ...............................................................................................................................................................................................
Normorphine (9313) ....................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
1-Phenylcyclohexylamine (7460) .................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................
Cocaine (9041) ............................................................................................................................................................................................
Codeine (9050) ............................................................................................................................................................................................
Dihydrocodeine (9120) ................................................................................................................................................................................
Ecgonine (9180) ..........................................................................................................................................................................................
Meperidine intermediate-B (9233) ...............................................................................................................................................................
Noroxymorphone (9668) ..............................................................................................................................................................................
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 22, 2013.
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
The company plans to manufacture
bulk active pharmaceutical ingredients
(APIs) for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. No other activity for this
drug code is authorized for this
registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 22, 2013.
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–12114 Filed 5–21–13; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2013–12115 Filed 5–21–13; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Drug Enforcement Administration
TKELLEY on DSK3SPTVN1PROD with NOTICES
Manufacturer of Controlled
Substances, Notice of Application,
Austin Pharma, Llc.
DEPARTMENT OF JUSTICE
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 28, 2013,
Austin Pharma, LLC., 811 Paloma Drive,
Suite C, Round Rock, Texas 78665–
2402, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Marihuana (7360), a
basic class of controlled substance listed
in schedule I.
Manufacturer of Controlled
Substances, Notice of Application, Lin
Zhi International, Inc.
VerDate Mar<15>2010
16:59 May 21, 2013
Jkt 229001
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 3, 2013, Lin
Zhi International, Inc., 670 Almanor
Avenue, Sunnyvale, California 94085,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
PO 00000
Frm 00066
Fmt 4703
Sfmt 9990
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
manufacturer of the following basic
classes of controlled substances:
Drug
Tetrahydrocannabinols
(7370)
3,4-Methylenedioxymeth- amphetamine (7405).
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Schedule
I
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances as bulk
reagents for use in drug abuse testing.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 22, 2013.
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–12110 Filed 5–21–13; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\22MYN1.SGM
22MYN1
]]>Agencies
[Federal Register Volume 78, Number 99 (Wednesday, May 22, 2013)]
[Notices]
[Page 30332]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-12110]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances, Notice of Application, Lin
Zhi International, Inc.
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on April 3, 2013, Lin Zhi
International, Inc., 670 Almanor Avenue, Sunnyvale, California 94085,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of the following basic
classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370) 3,4- I
Methylenedioxymeth- amphetamine (7405).
Cocaine (9041)............................. II
Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
as bulk reagents for use in drug abuse testing.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR Sec. 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 22, 2013.
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-12110 Filed 5-21-13; 8:45 am]
BILLING CODE 4410-09-P
